Indivior

News

CNS-focused Supernus and Indivior agree merger terms

Supernus Pharma and Indivior have signed an all-stock merger agreement that would establish a new CNS-focused company with annual sales of $2.2bn.

News

Indivior stops Opvee promotion in New York after settlement

Indivior has agreed to halt all marketing of its opioid overdose drug Opvee in New York after being rapped for mispromoting it to health officials.

News

Indivior changes CEO after warning sales will fall in 2025

UK-listed pharma company Indivior has appointed pharma veteran Joe Ciaffoni as its new chief executive, replacing Mark Crossley.

News

Indivior bags $111m contract from US for overdose therapy

Indivior has secured a $111 million supply contract from the US federal government for its intranasal therapy for treating opioid overdose, in a further boost to the UK co

News

Indivior relieves Suboxone hangover with $385m deal

Indivior has reached an agreement to settle all outstanding claims over allegations of improper marketing of its opioid use disorder drug Suboxone Film in the US.

News